Elham Alharbi
Research Subjects
Elham Alharbi has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Ghadi Abdulmuin Althobaiti
College of Medicine, Taif University, Taif, Saudi Arabia
1 shared publication Majed Al Qurashi
Al-hada Armed Forces Hospital, Taif, Saudi Arabia
1 shared publication- Osama Almajhadi
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
1 shared publication - Rana Alharthi
College of Medicine, Taif University, Taif, Saudi Arabia
1 shared publication
Latest Publications
- 24 October 2026
- Published by Discover STM Publishing Ltd. in Annals of Middle Eastern Medicine
- Vol. 2 (5) , 652-663
Efficacy and safety of reproxalap for the treatment of dry eye disease: a systematic review and meta-analysis
Background: Reproxalap, a reactive aldehyde species inhibitor, has been proposed for dry eye disease (DED), but trial findings are inconsistent, and no quantitative synthesis exists. We assessed the efficacy and safety of reproxalap 0.25% ophthalmic solution versus vehicle in adults with DED. Methods: PubMed, Web of Science, ClinicalTrials.gov, gray literature, and manufacturer sources were searched through June 2025 (International Prospective Register of Systematic Reviews CRD420251069765; Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020). Two reviewers independently screened, extracted data, and assessed risk of bias. Random- or fixed-effects models were used according to heterogeneity. Standardized mean differences (SMDs), mean differences (MDs), and risk ratios (RRs) were pooled with 95% confidence intervals (CIs). Certainty was assessed using Grading of Recommendations, Assessment, Development, and Evaluations. Results: Eight randomized controlled trials (1,436 participants) were included. Reproxalap did not significantly improve ocular dryness (SMD, −0.07; 95% CI, −0.24 to 0.10; I² = 47%; p = 0.43) or conjunctival redness (MD, −0.06; 95% CI, −0.19 to 0.07; I² = 73%; p = 0.36; random-effects). Tear production significantly increased (MD, 2.20 mm; 95% CI, 1.45-2.94; I² = 0%; p < 0.0001). Adverse events (AEs) were more frequent with reproxalap (overall RR, 16.30; 95% CI, 4.46-59.55; I² = 94%; p < 0.0001), although the magnitude of excess varied by study setting: chamber trials showed a larger effect (RR, 25.98; 95% CI, 15.17-44.48; I² = 0%), while field trials showed a smaller but still elevated risk (RR, 6.01; 95% CI, 1.25-28.85). Certainty was moderate for AEs and tear production, and very low for dryness and redness. Conclusion: Reproxalap 0.25% significantly increased tear production by 2.2 mm, although its clinical relevance is uncertain given the ≥10 mm responder threshold. No benefit was observed for ocular dryness or conjunctival redness. Larger, well-designed field trials are needed to confirm clinical benefit.
- 24 October 2026
- Published by Discover STM Publishing Ltd. in Annals of Middle Eastern Medicine
- Vol. 2 (5) , 652-663
Efficacy and safety of reproxalap for the treatment of dry eye disease: a systematic review and meta-analysis
Background: Reproxalap, a reactive aldehyde species inhibitor, has been proposed for dry eye disease (DED), but trial findings are inconsistent, and no quantitative synthesis exists. We assessed the efficacy and safety of reproxalap 0.25% ophthalmic solution versus vehicle in adults with DED. Methods: PubMed, Web of Science, ClinicalTrials.gov, gray literature, and manufacturer sources were searched through June 2025 (International Prospective Register of Systematic Reviews CRD420251069765; Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020). Two reviewers independently screened, extracted data, and assessed risk of bias. Random- or fixed-effects models were used according to heterogeneity. Standardized mean differences (SMDs), mean differences (MDs), and risk ratios (RRs) were pooled with 95% confidence intervals (CIs). Certainty was assessed using Grading of Recommendations, Assessment, Development, and Evaluations. Results: Eight randomized controlled trials (1,436 participants) were included. Reproxalap did not significantly improve ocular dryness (SMD, −0.07; 95% CI, −0.24 to 0.10; I² = 47%; p = 0.43) or conjunctival redness (MD, −0.06; 95% CI, −0.19 to 0.07; I² = 73%; p = 0.36; random-effects). Tear production significantly increased (MD, 2.20 mm; 95% CI, 1.45-2.94; I² = 0%; p < 0.0001). Adverse events (AEs) were more frequent with reproxalap (overall RR, 16.30; 95% CI, 4.46-59.55; I² = 94%; p < 0.0001), although the magnitude of excess varied by study setting: chamber trials showed a larger effect (RR, 25.98; 95% CI, 15.17-44.48; I² = 0%), while field trials showed a smaller but still elevated risk (RR, 6.01; 95% CI, 1.25-28.85). Certainty was moderate for AEs and tear production, and very low for dryness and redness. Conclusion: Reproxalap 0.25% significantly increased tear production by 2.2 mm, although its clinical relevance is uncertain given the ≥10 mm responder threshold. No benefit was observed for ocular dryness or conjunctival redness. Larger, well-designed field trials are needed to confirm clinical benefit.